The Priority Review

Tag

MSC therapies

1 story

Stories

  1. Policy

    Dechra acquires biotechnology company Gallant Pet Inc

    Dechra completed its acquisition of Gallant Pet Inc, a U.S.-based animal health biotechnology company that develops off-the-shelf mesenchymal stromal cell therapies for pets. The transaction terms are confidential and the first innovation from Gallant's pipeline is anticipated as early as 2027.